Health
AstraZeneca and Ionis to present data on failed heart drug eplontersen at Munich conference
Cardiologists and investors await details on why the drug failed to show significant benefits in treating ATTR-CM, a outcome affecting Alnylam Pharmaceuticals.
The short version
- AstraZeneca and Ionis Pharmaceuticals are scheduled to present detailed data at the European Society of Cardiology Congress in Munich explaining why their drug, eplontersen, failed in a clinical trial.
- The drug failed to significantly reduce cardiovascular deaths or recurrent events compared to a placebo in patients with ATTR-CM, a rare heart condition.
- The clinical failure has created uncertainty for Alnylam Pharmaceuticals, which is developing two of its own treatments for the same disease.
Key facts
- The European Society of Cardiology Congress begins on Friday in Munich.[STAT]
- AstraZeneca and Ionis Pharmaceuticals will share new details at the conference regarding the failure of their drug, eplontersen.[STAT]
- Eplontersen failed to significantly reduce the risk of cardiovascular deaths or recurrent events compared to a placebo in patients with ATTR-CM.[STAT]
- The failure of eplontersen has clouded the outlook for Alnylam Pharmaceuticals' two competing ATTR-CM drugs.[STAT]
What remains uncertain
- The specific scientific reasons behind why eplontersen failed to outperform the placebo remain to be disclosed in detail at the upcoming conference.[STAT]